Posts

New Novartis ESC data highlights strength of cardiovascular portfolio

New Novartis ESC data highlights strength of cardiovascular portfolio
arcticnovartis

PRESS RELEASE

/by
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
arcticnovartis

/by
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben

Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR 

/by
Novartis receives approval for first malaria medicine for newborn babies and young infants

Novartis receives approval for first malaria medicine for newborn babies and young infants
arcticnovartis

  • Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants
  • Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic)
  • Novartis plans to introduce infant-friendly Coartem Baby on largely not-for-profit basis to increase access in areas where malaria is endemic

Basel, July 8, 2025 – Novartis today announced Coartem

/by
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
arcticnovartis

  • The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1
  • Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

/by
Novartis completes acquisition of Regulus Therapeutics

Novartis completes acquisition of Regulus Therapeutics
arcticnovartis

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

/by
Novartis announces expiration of Regulus Therapeutics tender offer

Novartis announces expiration of Regulus Therapeutics tender offer
arcticnovartis

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc.

/by